ATC code: D11AH02
One study showed similar effect of treatment with pimecrolimus in men and women with Behcet’s disease. Controlled studies on differences between men and women regarding safety and pharmacokinetics are however lacking.
The present evidence concerning differences between men and women is very limited and do not motivate differentiation in dosing or treatment.
No difference between men and women has been shown for transdermal absorption in general [1].
A randomized double-blind placebo-controlled study (41 men, 49 women) of treatment with pimecrolimus cream in genital ulcers from Behcet’s disease showed similar effect in men and women [2].
No studies with a clinically relevant sex analysis regarding adverse effects of pimecrolimus have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Updated: 2020-08-28
Date of litterature search: 2017-03-24
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson